Remove 2013 Remove Molecular Biology Remove Therapies
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105
article thumbnail

Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabsf

The Pharma Data

Senior Vice President, Early Clinical Development, Hematology/ Oncology and Cell Therapy and San Francisco point head. “ A private,non-profit institution, LabCentral was innovated in 2013 as a helipad for high implicit life- lores and biotech startups. Since opening in 2013, MBC BioLabs has helped launch and grow 230 companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket

The Pharma Data

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

article thumbnail

Using AI to predict metastatic behaviour of NSCLC

Drug Target Review

How have recent advancements in immune checkpoint blockade therapy affected outcomes for primary NSCLC? Dr Govindan : Even though immunotherapy and chemotherapy given after surgery improve the overall survival, as Dr Cote said, many may not need those therapies and a good number of them recur despite post operative systemic therapies.

article thumbnail

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

The Pharma Data

This is a landmark study in converting the power of lethal botulinum neurotoxins into therapies. About CytoDel CytoDel is a privately held biopharmaceutical company that uses the tools of 21st century molecular biology to produce recombinant derivatives of botulinum neurotoxin customized to specific applications.

Science 52
article thumbnail

The Codon Guide to Synthetic Biology

Codon

Journal of Molecular Biology (1961). Link (Golden Gate assembly) Other Basic Methods & Cloning →Basic Methods in Cellular and Molecular Biology , by multiple authors. PNAS (2013). Link Molecular Cloning Techniques , by AddGene. Molecular Biology of the Cell, 4th Edition.

DNA 98
article thumbnail

Levers for Biological Progress

Codon

I’ve chosen these two because I think they are the linchpin by which we’ll be able to build broadly useful AI models for cell and molecular biology. But looking ahead to the second bottleneck, what does it mean to say that biology is “complex”?

DNA 128